Immuno-oncology
From the Journals
Is cancer immunotherapy more effective in men than women?
Cancer immunotherapy with checkpoint inhibitors appears to achieve greater mortality reductions in men than in women, regardless of drug or cancer...
From the Journals
Checkpoint inhibitors get to patients quickly
Within about 4 months of FDA approval of PD-1 inhibitors, the majority of patients with melanoma, NSCLC, and RCC began receiving these agents.
Conference Coverage
New drugs provide new options in HCC
PHILADELPHIA – “We are on the cusp where new compounds not only are being tested, but they are being approved.”
Conference Coverage
Early results favorable for combo TLR9 agonist + pembro in advanced melanoma
CHICAGO – The combination of pembrolizumab with CMP-001 is being evaluated as a strategy to overcome resistance to PD-1 blockade for patients with...
Conference Coverage
KEYNOTE-054: Adjuvant pembrolizumab beat placebo in high-risk resected melanoma
CHICAGO – One-year rates of recurrence-free survival for adjuvant pembrolizumab and placebo were 75% and 61%, respectively, in a phase 3 trial of...
From the Journals
Blinatumomab triggers complete MRD response in ALL
Complete MRD response was associated with improved relapse-free and overall survival.
Conference Coverage
Surgery after immunotherapy effective in advanced melanoma
CHICAGO – Five-year survival was 75% in selected patients with advanced melanoma who had resection to no evidence of disease after immunotherapy...
Conference Coverage
Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC
ORLANDO – Checkpoint blockade associated with less combined direct and indirect toxicity, a systematic review and meta-analysis suggests.
From the Journals
Nivolumab helps some with advanced NSCLC reach 5-year mark
For 129 patients with previously treated advanced non-small cell lung cancer, the estimated 5-year overall survival rate was 16%.
Conference Coverage
HDAC inhibition may boost immune therapy efficacy in breast cancer
ORLANDO – Entinostat and nivolumab with or without ipilimumab showed encouraging activity in early results from a phase 1 trial of patients with...
Conference Coverage
Chemotherapy, metabolic pathway may affect CAR T-cell potential
Chemotherapy, especially with cyclophosphamide and doxorubicin, seems particularly toxic to T cells.